World

ARCA Biopharma ReceiveD FDA Orphan Drug Designation For rNAPc2 As A Potential Treatment For Ebola

ARCA Biopharma ReceiveD FDA Orphan Drug Designation For rNAPc2 As A Potential Treatment For Ebola

Jan. 29 | ARCA biopharma, Inc.,  a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, announced that the U.S. Food and Drug Administration... Read more »

Advertisement

Content Protected Using Blog Protector Plugin By: Make Money.